The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
 
Rana R. McKay
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Lillian Werner
No Relationships to Disclose
 
Alexandra Jones
No Relationships to Disclose
 
Atish Dipankar Choudhury
Employment - LeMaitre Vascular (I)
Research Funding - Janssen (Inst)
 
Mark Pomerantz
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen Biotech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Glenn J. Bubley
No Relationships to Disclose
 
Susan F. Slovin
Consulting or Advisory Role - Bayer
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Endocyte
Research Funding - Bayer (Inst); Endocyte (Inst); Progenics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Endocyte
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Metamark Genetics; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Cristal Therapeutics; Druggablity Technologies; Endocyte; Genentech/Roche; GTx; Ipsen; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Pfizer; Progenity; Sanofi; Sotio; Tarveda Therapeutics; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Sanofi
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Clovis Oncology; Dava Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Parexel; Research to Practice; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation; Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals